Product Description
Synapsinae is a potent Glycine Transporter 1 (GlyT-1) inhibitor. Inhibition of GlyT-1 can block glycine uptake and enhance the function of NMDA receptor. (Sourced from: https://www.syneurx.com/research/#pipeline)
Mechanisms of Action: GlyT1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SyneuRx
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dementia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/07/2024 |
PubMed |
Synapsin E-domain is essential for alpha-synuclein function. |
|
05/03/2024 |
PubMed |
Nurr1 overexpression in the primary motor cortex alleviates motor dysfunction induced by intracerebral hemorrhage in the striatum in mice. |
|
04/30/2024 |
PubMed |
Melatonin Enhances Neural Differentiation of Adipose-Derived Mesenchymal Stem Cells. |